Ipsen Finalizes Acquisition of Kartos Therapeutics, Integrates Phase III MDM2 Inhibitor Navtemadlin into Myelofibrosis Treatment Pipeline

Ipsen Finalizes Acquisition of Kartos Therapeutics, Integrates Phase III MDM2 Inhibitor Navtemadlin into Myelofibrosis Treatment Pipeline →

Ipsen SA (Euronext: IPN; ADR: IPSEY; reference: 0MH6), a Paris-based global biopharmaceutical leader, announced on 21 August 2026 the completion of its acquisition of Kartos Therapeutics, a clinical-stage biopharma company. This acquisition…